An­oth­er Covid-19 an­ti­body cock­tail on the menu? Brii Bio touts ear­ly win in NIH study for a com­bo al­ready used in Chi­na

Months af­ter flop­ping in an NIH-spon­sored study, Brii Bio­sciences’ Covid-19 an­ti­body com­bo has re­deemed it­self in a sec­ond tri­al.

The biotech says its an­ti­bod­ies — which had hailed from Bei­jing’s Ts­inghua Uni­ver­si­ty and Shen­zhen Third Peo­ple’s Hos­pi­tal — dra­mat­i­cal­ly im­proved pa­tients’ odds of get­ting hos­pi­tal­ized or dy­ing over place­bo, notch­ing a sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tion of 78%. That trans­lates to a risk ra­tio of 0.22 (95% con­fi­dence in­ter­val: 0.05, 0.86; p<.00001).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER